Table 1.
CD19 expression at the time of first referral to NIH and the first change in CD19 expression from referral.
| Therapy received prior to referral (n = total # who received therapy, # with CR) | CD19 expression at referral (n, %) [median CD19 ABC or %CD19-positive blasts (IQR)] | Interval therapies received (n) | Median days to ↑ CD19 expression (IQR) | First change in CD19 expression (n, %) |
|---|---|---|---|---|
|
| ||||
| CD19-CAR (16, 14) Blinatumomab (3, 2) Both (3, 3a) Other CD19 targetedb (1,0) None (0) |
CD19 negative (23, 41%) [N/A] |
No immunotherapy (1) Stem cell transplant (1) CD22 CAR (15) Inotuzumab (4) Moxetumomab (2) |
NA | Remains CD19 neg (17, 74%) |
| No immunotherapy (2) Stem cell transplant (1) CD22 CAR (2) Inotuzumab (1) Moxetumomab (1) Daratumomab (1) |
133 (351) | Becomes CD19 partial (4, 17%) | ||
| Stem cell transplant (1) CD22 CAR (2) |
416 (39) | Becomes CD19 positive (2, 9%) | ||
| CD19-CAR (1,0) Blinatumomab (5,2) Both (0) None (2) |
CD19 partialc (8, 14%) [68% (59%, 86%)] |
NA | NA | Becomes CD19 neg (0, 0%) |
| No immunotherapy (1) Stem cell transplant (1) CD22 CAR (3) | NA | Remains CD19 partial (4, 50%) | ||
| No immunotherapy (2) CD22 CAR (2) |
53 (66) | Becomes CD19 positive (4, 50%) | ||
| CD19-CAR (5,5) Blinatumomab (9,5) Both (4,2a) None (7) |
CD19 positive (25, 45%) [9004 (4181, 16,240); dimd: 446] |
Stem cell transplant (1) CD22 CAR (1) CD19-CAR (1) Moxetumomab (1) Blinatumomab (1) |
NA | Becomes CD19 nege (2, 8%) |
| No immunotherapy (2) CD19-CAR (1) |
NA | Becomes CD19 partial (3, 12%) | ||
| No immunotherapy (1) | 21 (NA) | CD19 dim → positive (1, 4%) | ||
| No immunotherapy (4) CD22 CAR (14) CD19-CAR (5) CD19/22 CAR (1) Inotuzumab (2) Moxetumomab (1) |
NA | Remains CD19 positivef (19, 76%) | ||
ABC antibody-binding capacity, CR complete remission, IQR interquartile range, CAR chimeric antigen receptor therapy
a
No response to blinatumomab, complete response to CD19-CAR.
b
SGN19a.
c
Partial positivity defined by < 95% antigen positive.
d
Dim defined as CD19 expression < 2000 sites/cell.
e
Following interval CD19-targeted therapy.
f
One patient was CD19-dim and remained CD19-dim.